Drug Profile
Ricolinostat - Regenacy Pharmaceuticals
Alternative Names: ACY-1215; ACY-63; RocilinostatLatest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Dana-Farber Cancer Institute; Harvard University
- Developer 3E-Regenacy Pharmaceuticals (BC Regenacy); Columbia University; Dana-Farber Cancer Institute; Regenacy Pharmaceuticals
- Class Amides; Antineoplastics; Hydroxamic acids; Pyrimidines; Small molecules
- Mechanism of Action HDAC6 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Diabetic neuropathies; Multiple myeloma
- Phase I/II Lymphoma
- Phase I Peripheral nervous system diseases
- No development reported Breast cancer; Charcot-Marie-Tooth disease; Chronic lymphocytic leukaemia; Fallopian tube cancer; Malignant melanoma; Ovarian cancer; Peritoneal cancer
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Charcot-Marie-Tooth-disease in USA (PO)
- 10 Nov 2023 3E-Regenacy Pharmaceuticals (BC Regenacy) completes a phase I trial in Peripheral nervous system diseases in China (PO) (NCT05229042)
- 28 Apr 2023 Regenacy Pharmaceuticals completes a phase II trial for Diabetic neuropathies (In adults, In the elderly) in USA (PO) (NCT03176472)